دورية أكاديمية
Clinical Management of Patients with Non-Small Cell Lung Cancer, Brain Metastases, and Actionable Genomic Alterations: A Systematic Literature Review
| العنوان: | Clinical Management of Patients with Non-Small Cell Lung Cancer, Brain Metastases, and Actionable Genomic Alterations: A Systematic Literature Review |
|---|---|
| المؤلفون: | Khasraw, Mustafa, Yalamanchili, Priyanka, Santhanagopal, Anu, Wu, Chuntao, Salas, Maribel, Meng, Jie, FELIP, ENRIQUETA |
| المساهمون: | Institut Català de la Salut, Khasraw M The Duke Cancer Institute, School of Medicine, Duke University, Durham, NC, USA. Yalamanchili P, Santhanagopal A, Wu C Daiichi Sankyo, Inc, Basking Ridge, NJ, USA. Salas M Daiichi Sankyo, Inc, Basking Ridge, NJ, USA. University of Pennsylvania, Philadelphia, PA, USA. Meng J Daiichi Sankyo Europe GmbH, Munich, Germany. Felip E Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus |
| المصدر: | Scientia |
| بيانات النشر: | Springer |
| سنة النشر: | 2024 |
| مصطلحات موضوعية: | Cervell - Càncer - Aspectes genètics, Pulmons - Càncer - Aspectes genètics, Anomalies cromosòmiques, Genòmica, DISEASES::Neoplasms::Neoplasms by Site::Thoracic Neoplasms::Respiratory Tract Neoplasms::Lung Neoplasms::Bronchial Neoplasms::Carcinoma, Bronchogenic::Carcinoma, Non-Small-Cell Lung, DISEASES::Neoplasms::Neoplasms by Site::Nervous System Neoplasms::Central Nervous System Neoplasms::Brain Neoplasms, Other subheadings::Other subheadings::Other subheadings::/drug therapy, PHENOMENA AND PROCESSES::Genetic Phenomena::Genetic Variation::Mutation, DISCIPLINES AND OCCUPATIONS::Natural Science Disciplines::Biological Science Disciplines::Biology::Computational Biology::Genomics, ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias torácicas::neoplasias del tracto respiratorio::neoplasias pulmonares::neoplasias de los bronquios::carcinoma broncogénico::carcinoma de pulmón de células no pequeñas, ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias del sistema nervioso::neoplasias del sistema nervioso central::neoplasias cerebrales, Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia, FENÓMENOS Y PROCESOS::fenómenos genéticos::variación genética::mutación, DISCIPLINAS Y OCUPACIONES::disciplinas de las ciencias naturales::disciplinas de las ciencias biológicas::biología::biología computacional::genómica |
| الوصف: | EGFR mutation; Brain metastases; NSCLC ; Mutación EGFR; Metástasis cerebrales; NSCLC ; Mutació EGFR; Metàstasis cerebrals; NSCLC ; Introduction Nearly 60% of patients with non-small cell lung cancer (NSCLC) present with metastatic disease, and approximately 20% have brain metastases (BrMs) at diagnosis. During the disease course, 25–50% of patients will develop BrMs. Despite available treatments, survival rates for patients with NSCLC and BrMs remain low, and their overall prognosis is poor. Even with newer agents for NSCLC, options for treating BrMs can be limited by their ineffective transport across the blood–brain barrier (BBB) and the unique brain tumor microenvironment. The presence of actionable genomic alterations (AGAs) is a key determinant of optimal treatment selection, which aims to maximize responses and minimize toxicities. The objective of this systematic literature review (SLR) was to understand the current landscape of the clinical management of patients with NSCLC and BrMs, particularly those with AGAs. Method A Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA)-compliant SLR was conducted to identify studies in patients with BrMs in NSCLC. Searches used the EMBASE and MEDLINE® databases, and articles published between January 1, 2017 and September 26, 2022 were reviewed. Results Overall, 179 studies were included in the SLR. This subset review focused on 80 studies that included patients with NSCLC, BrMs, and AGAs (19 randomized controlled trials [RCTs], two single-arm studies, and 59 observational studies). Sixty-four of the 80 studies reported on epidermal growth factor receptor (EGFR) mutations, 14 on anaplastic lymphoma kinase (ALK) alterations, and two on both alterations. Ninety-five percent of studies evaluated targeted therapy. All RCTs allowed patients with previously treated, asymptomatic, or neurologically stable BrMs; the percentage of asymptomatic BrMs varied across observational studies. Conclusions Although targeted therapies demonstrate systemic ... |
| نوع الوثيقة: | article in journal/newspaper |
| وصف الملف: | application/pdf |
| اللغة: | English |
| تدمد: | 1865-8652 |
| العلاقة: | Advances in Therapy;41; https://doi.org/10.1007/s12325-024-02799-9Test; Khasraw M, Yalamanchili P, Santhanagopal A, Wu C, Salas M, Meng J, et al. Clinical Management of Patients with Non-Small Cell Lung Cancer, Brain Metastases, and Actionable Genomic Alterations: A Systematic Literature Review. Adv Ther. 2024 May;41:1815–1842.; https://hdl.handle.net/11351/11398Test; 001188046600001 |
| DOI: | 10.1007/s12325-024-02799-9 |
| الإتاحة: | https://doi.org/10.1007/s12325-024-02799-9Test https://hdl.handle.net/11351/11398Test |
| حقوق: | Attribution-NonCommercial 4.0 International ; http://creativecommons.org/licenses/by-nc/4.0Test/ ; info:eu-repo/semantics/openAccess |
| رقم الانضمام: | edsbas.E8333D1E |
| قاعدة البيانات: | BASE |
| تدمد: | 18658652 |
|---|---|
| DOI: | 10.1007/s12325-024-02799-9 |